N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance
2007

HIV Mutation N348I Causes Drug Resistance

Sample size: 1009 publication 10 minutes Evidence: high

Author Information

Author(s): Yap Soo-Huey, Sheen Chih-Wei, Fahey Jonathan, Zanin Mark, Tyssen David, Lima Viviane Dias, Wynhoven Brian, Kuiper Michael, Sluis-Cremer Nicolas, Harrigan P. Richard, Tachedjian Gilda

Primary Institution: British Columbia Centre for Excellence in HIV/AIDS

Hypothesis

The study aims to establish the in vivo relevance of the N348I mutation in HIV-1 reverse transcriptase and its role in drug resistance.

Conclusion

The N348I mutation in HIV-1 reverse transcriptase is prevalent in treated individuals and confers resistance to both zidovudine and nevirapine.

Supporting Evidence

  • N348I increased in prevalence from below 1% in treatment-naïve individuals to 12.1% in treatment-experienced patients.
  • N348I was associated with significant increases in viral load.
  • N348I conferred 2- to 4-fold resistance to zidovudine.
  • N348I decreased susceptibility to nevirapine by 7.4-fold.
  • N348I was the first mutation observed in some patients during virological failure.
  • N348I was highly associated with thymidine analogue mutations and NNRTI resistance mutations.
  • The emergence of N348I can significantly impact patient responses to antiretroviral therapies.

Takeaway

Scientists found a common mutation in HIV that makes it harder to treat with certain drugs, showing that this mutation can appear early in treatment.

Methodology

The study analyzed clinical isolates from the British Columbia Centre for Excellence in HIV/AIDS, focusing on the prevalence of the N348I mutation and its association with drug resistance mutations.

Limitations

The study does not account for the simultaneous selection of other drug resistance mutations that may also contribute to viral load increases.

Participant Demographics

The study included treatment-naïve and treatment-experienced individuals from the British Columbia Centre for Excellence in HIV/AIDS.

Statistical Information

P-Value

7.7 × 10−12

Confidence Interval

95% confidence interval 1.43–4.81

Statistical Significance

p < 0.001

Digital Object Identifier (DOI)

10.1371/journal.pmed.0040335

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication